New tool aims to ease tough talks on cancer drug resistance
NCT ID NCT04118062
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study aimed to create a communication tool to help doctors and patients discuss when cancer stops responding to treatment. Researchers interviewed 128 people, including patients with certain breast cancers, metastatic uveal melanoma, parents of children with cancer, and healthcare experts. Through surveys and group discussions, they developed a booklet to guide these conversations and improve shared decision-making.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could create a practical booklet to improve how doctors and patients talk about treatment resistance, making these difficult conversations clearer and more supportive.
- What could go wrong
- This is a small, completed study focused on developing a tool, not testing a treatment. The tool may not work well in all settings or for all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUMINAL B BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institut Curie
Paris, 75005, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a High-Fiber diet shield the gut during breast cancer therapy?
- Can a drug duo tame a rare eye cancer that has spread?
- Can a Tumor's genetic blueprint guide better treatment for kids with brain cancer?
- Can a shorter chemo combo tame High-Risk neuroblastoma?
- Can mapping tumor DNA unlock personalized breast cancer care?
- Can a Two-Pronged antibody boost Chemo's power against a tough breast cancer?